AXLRx Book a callCommission
Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Module 01

Competitive Intelligence

Who controls which cohort, and on what evidence?

43 in the library 5 markets 72h to deliverable

What you receive

Working files, not a slide of prose.

PDF brief · Excel competitive grid · PowerPoint readout. Scope confirmed in 24 hours, delivered in 72.

In the library

Competitive Intelligence the engine has already run.

United StatesUS Alzheimer's Disease Competitive IntelligenceLecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.United StatesUS Atopic Dermatitis Competitive IntelligenceDupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.United StatesUS MASH Competitive IntelligenceRezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.United StatesUS NSCLC Competitive IntelligenceFour approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.United StatesUS Obesity Competitive IntelligenceTirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.United StatesUS PNH Competitive IntelligenceIptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).United StatesUS Type 2 Diabetes Competitive IntelligenceTirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.United StatesUS IgA Nephropathy Competitive IntelligenceFrom zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.United StatesUS Hereditary Angioedema Competitive IntelligenceThe prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field.

All 43 in the library

Competitive Intelligence: questions buyers ask

What is pharmaceutical competitive intelligence?

Pharmaceutical competitive intelligence maps who controls which patient cohort in a market, on what clinical and access evidence, and where a new asset can win. AXLRx builds it asset by asset, with every figure traced to its source.

How is AI used in pharma competitive intelligence at AXLRx?

The AI engine plans the retrieval, reads trial, regulatory and payer sources and drafts the competitive matrix. It is never the source of a figure: each claim is found in the document it cites, and a consultant reads the result before it ships.

How long does a competitive intelligence analysis take?

Scope is confirmed within 24 hours and the deliverable arrives within 72 hours.

Run Competitive Intelligence on your asset.